Strumento inattivo

Altre lingue CROSSJECT Euronext Paris

Azioni

Prezzo di chiusura Euronext Paris Altri mercati azionari
- ^EUR	-

13/06	Crossject SA annuncia la nomina di Dan Chiche a Chief Medical Officer per il Nord America	CI
05/06	Crossject: aumento di capitale di successo	CF

Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	27/06
Crossject : Document AMF CP. 2024DD982992	26/06
Crossject : Document AMF CP. 2024DD982993	26/06
Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.	26/06
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	26/06
Crossject : Document AMF CP. 2024DD982585	24/06
Crossject : Document AMF CP. 2024DD971458	17/06
Crossject SA Announces the Appointment of Dan Chiche as Chief Medical Officer North America	13/06
Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord	12/06
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America	12/06
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America	12/06
Crossject : Document AMF CP. 2024DD970268	10/06
Crossject : Document AMF CP. 2024DD970211	10/06
Crossject : Document AMF CP. 2024DD970091	10/06
Crossject : Document AMF CP. 2024DD970037	07/06
Webcast : résultats annuels 2023 et stratégie de développement	06/06
Crossject : succès de l'augmentation de capital	05/06
CROSSJECT : Succès de l'augmentation de capital	05/06
CROSSJECT : Success of the capital increase	05/06
Les marchés restent à l'horizontale	05/06

Non ci sono risultati per questa ricerca